As rimonabant treatment, gastric phospho-S6K1 responded to AM281 treatment in a manner similar to that pmTOR, although the phospho-S6K1 response did not reach statistical significance (control: 100 vs AM281: 116.71±9.04 pS6K1/S6K1; no significant difference, Figure 8B ).
← all excerpts
The gastric CB1 receptor modulates ghrelin production through the mTOR pathway to regulate food intake.
1
—
—